Trial intelligence / Profile preview

Insulin degludec simple versus stepwise titration in insulin-naive adults with type 2 diabetes

2010-022337-29Phase 3Completed

Sponsor
Novo Nordisk
Start
Dec 2010
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change from baseline in HbA1c after 26 weeks and Noninferiority of simple versus stepwise titration algorithm. Started Dec 2010; status: completed.

02

Drugs

insulin degludec
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on 2010-022337-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022337-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call